Literature DB >> 28239785

Pharmacological Analysis of the Therapeutic Effect of Radioprotectors Cystamine and Indralin in the Capacity of Radiomitigators.

M V Vasin1, I B Ushakov2, V Yu Kovtun3, S N Komarova2, L A Semenova2, A A Galkin2, R V Afanas'ev2, I V Bukhtiyarov2.   

Abstract

The therapeutic radiomitigating effect of cystamine and indralin was studied in experiments on mice and rats and pharmacological analysis of these drugs was carried out. The animals were subjected to whole-body 60Co γ-irradiation. The mice were exposed to single (9-10 Gy) or double (8 Gy) irradiation with an interval of 1 month. The rats were exposed to 10 Gy with partial shielding of the upper quarter of the abdomen. In experiments on mice, pretreatment with reserpine abolished the therapeutic effect of cystamine administered repeatedly every 15 min over 1 h after irradiation. Moreover, summation of the radioprotective and therapeutic effects of the radioprotector was revealed under these conditions. In mice and rats, α1-adrenoreceptor blocker terazosin did not abolish the therapeutic effect of indralin administrated after irradiation, but blocked the radioprotective effect of indralin applied prior to irradiation. At the same time, 5-HT2 serotonin receptor blocker tropoxin abolished the therapeutic effect of indralin without affecting its radioprotective activity.

Entities:  

Keywords:  cystamine; indralin; shielding; terazosin; tropoxin

Mesh:

Substances:

Year:  2017        PMID: 28239785     DOI: 10.1007/s10517-017-3641-1

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  2 in total

1.  Antioxidant Supplementation: A Linchpin in Radiation-Induced Enteritis.

Authors:  Mumtaz Anwar; Shabeer Ahmad; Reyhan Akhtar; Akhtar Mahmood; Safrun Mahmood
Journal:  Technol Cancer Res Treat       Date:  2017-05-22

2.  Preclinical Evaluation of Safety, Pharmacokinetics, Efficacy, and Mechanism of Radioprotective Agent HL-003.

Authors:  Yahong Liu; Longfei Miao; Yuying Guo; Hongqi Tian
Journal:  Oxid Med Cell Longev       Date:  2021-02-19       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.